| In this editorial, the issues raised in each of the articles included in this supplement issue of Diabetes Therapy are introduced, including their focus on reappraisal of sulfonylureas (SUs) in the treatment of type 2 diabetes mellitus (T2DM). |
| SUs have been available for over 50 years, with the latest generation of SUs associated with effective antihyperglycaemic efficacy but a lower risk of adverse effects relative to earlier generations of SUs. |
| The wide clinical benefits of SU treatment in T2DM are reviewed in this supplement, as well as how international and national guidelines recommend their use in patients with T2DM. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.